Live Breaking News & Updates on மைக்கேல் ஸ்க்னீடர்ஸ்
Stay updated with breaking news from மைக்கேல் ஸ்க்னீடர்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BRAIN Biotech AG expands stake in successful enzyme producer Biocatalysts Ltd. DGAP-News: BRAIN Biotech AG / Key word(s): Investment 12.05.2021 / 16:30 Zwingenberg, Germany, May 12, 2021 BRAIN Biotech AG expands stake in successful enzyme producer Biocatalysts Ltd. BRAIN has acquired additional shares in Biocatalysts Ltd. Biocatalysts strong business trend Planned additional capacity expansion now targeted earlier BRAIN Biotech AG has expanded its shareholdings in the successful enzyme producer Biocatalysts Ltd., Wales, to 82.2% by the purchase of additional shares from minority shareholders. Due to the strong business performance at Biocatalysts Ltd. current production capacity will be fully utilised although only coming on stream in early 2021. The 2nd phase of expansion is planned to be accelerated as a result. ....
- Different commercialization models currently being explored BRAIN Biotech AG has successfully completed the first development phase for a novel genome editing CRISPR Cas system applying its advanced metagenomics sequencing and protein engineering capabilities. BRAIN s technology enabled by a novel and independent Non-CAS9-Nuclease will significantly speed up in-house developments and promises significant economic upside. Genome editing has lately become one of the most exciting technologies in biotechnology. It allows for the directed and precise insertion, deletion or modification in the genome of a living organism. The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science. ....
A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so; ....
- Different commercialization models currently being explored BRAIN Biotech AG has successfully completed the first development phase for a novel genome editing CRISPR Cas system applying its advanced metagenomics sequencing and protein engineering capabilities. BRAIN s technology enabled by a novel and independent Non-CAS9-Nuclease will significantly speed up in-house developments and promises significant economic upside. Genome editing has lately become one of the most exciting technologies in biotechnology. It allows for the directed and precise insertion, deletion or modification in the genome of a living organism. The CRISPR-CAS system has provided a genetic tool with speed as well as simplicity that was previously unavailable to science. ....
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results 26.02.2021 / 07:30 Zwingenberg, Germany, 26. February 2021 BRAIN AG Q1 20/ 21 Results Strong performance of Biocatalysts Solid Cash Position Today, B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) published its results for the first quarter of the financial year 2020/21. Group revenues in the reporting period from October 1, 2020 to December 31, 2020 decreased by 21.7 % to € 8.1 million from € 10.3 million. This is mainly attributable to the BioScience segment which has a highly volatile revenue recognition quarter on quarter due to timing effects and milestone payments. The Group adjusted EBITDA decreased to € -1.4 million from € -0.2 million in the first three months of the 2020/21 financial year. ....